180 related articles for article (PubMed ID: 21211972)
21. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
[TBL] [Abstract][Full Text] [Related]
22. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
[TBL] [Abstract][Full Text] [Related]
23. Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis.
Dyckman AJ; Langevine CM; Quesnelle C; Kempson J; Guo J; Gill P; Spergel SH; Watterson SH; Li T; Nirschl DS; Gillooly KM; Pattoli MA; McIntyre KW; Chen L; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):383-6. PubMed ID: 21087862
[TBL] [Abstract][Full Text] [Related]
24. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
25. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
26. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
Lu B; Cao H; Cao J; Huang S; Hu Q; Liu D; Shen R; Shen X; Tao W; Wan H; Wang D; Yan Y; Yang L; Zhang J; Zhang L; Zhang L; Zhang M
Bioorg Med Chem Lett; 2016 Feb; 26(3):819-823. PubMed ID: 26739779
[TBL] [Abstract][Full Text] [Related]
27. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
29. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
[TBL] [Abstract][Full Text] [Related]
30. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
Wenglowsky S; Moreno D; Rudolph J; Ran Y; Ahrendt KA; Arrigo A; Colson B; Gloor SL; Hastings G
Bioorg Med Chem Lett; 2012 Jan; 22(2):912-5. PubMed ID: 22209462
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
32. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
[TBL] [Abstract][Full Text] [Related]
33. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines.
Buckley GM; Fosbeary R; Fraser JL; Gowers L; Higueruelo AP; James LA; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(12):3656-60. PubMed ID: 18501603
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
36. Identification of 4-aryl-1H-pyrrole[2,3-b]pyridine derivatives for the development of new B-Raf inhibitors.
Pinzi L; Anighoro A; Bajorath J; Rastelli G
Chem Biol Drug Des; 2018 Jul; 92(1):1382-1386. PubMed ID: 29469983
[TBL] [Abstract][Full Text] [Related]
37. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
[TBL] [Abstract][Full Text] [Related]
38. Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.
Newhouse BJ; Wenglowsky S; Grina J; Laird ER; Voegtli WC; Ren L; Ahrendt K; Buckmelter A; Gloor SL; Klopfenstein N; Rudolph J; Wen Z; Li X; Feng B
Bioorg Med Chem Lett; 2013 Nov; 23(21):5896-9. PubMed ID: 24042006
[TBL] [Abstract][Full Text] [Related]
39. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
40. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
